Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
rosacea eczema alopecia ceramide keratosis pityriasis basal cell melanoma keratosis purpuraYour Article Summary
See Latest ArticlesLong-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis
International Journal of Dermatology, 11/25/09
Foley P et al. – Efalizumab, 1.0 mg/kg/week, is effective and well tolerated in a 'real world' clinical setting, providing enduring reduction of psoriasis symptoms for up to 21 months.
Related Articles
Pediatric psoriasis: an update
Therapeutics and Clinical Risk Management, 10/22/09
Relevance Score: 95%
FDA Approves New Drug to Treat Psoriasis
Internet Source, 11/02/09
Relevance Score: 91%
Study shows major burden of psoriasis
Internet Source, 10/29/09
Relevance Score: 91%
Prevalence of myocardial infarction in patients with psoriasis in central China
Journal of the European Academy of Dermatology and Venereology, 10/27/09
Relevance Score: 91%
Why nail psoriasis remains difficult to treat
Dermatology in Practice, 10/12/09
Relevance Score: 91%
Today in Psoriasis...keeping you current
Receive free subspecialty "5-minute updates" via email
Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre
British Journal of Dermatology, 02/09/10
Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data
Rheumatismo, 02/09/10
Deficient SOCS3 and SHP-1 Expression in Psoriatic T Cells
Journal of Investigative Dermatology, 02/08/10
Article Search
Sponsor
Sponsor